A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with atrial fibrillation lose weight.

Who can join: Adults 18 to 80, have atrial fibrillation, BMI 35+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Ali AminianDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 100

What this study is for

Primary condition: Atrial Fibrillation. Also studied in: Obesity and Obesity-related Medical Conditions.

Full scientific study title: Metabolic Surgery for Atrial Fibrillation Elimination.

Who can join

Age18 to 80SexAnyBMI35 to 65

Adults 18 to 80, have atrial fibrillation, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Is a candidate for general anesthesia
Is eligible for metabolic surgery (RYGB or SG)
Is ≥18 and ≤80 years old
has a BMI ≥35 and ≤65 kg/m2
has AF criteria, which:

Key exclusion criteria

Significant cardiac valvular disease (planned to undergo cardiac valve intervention/surgery in the next 12 months)
Significant atherosclerotic disease (planned to undergo coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V
Classified as New York Heart Association Class IV
Left ventricular ejection fraction \<20% at the time of screening

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Ohio1 site

The Cleveland Clinic
Cleveland, Ohio
Chytaine Hall(216) 445-3983hallc1@ccf.org

Follow this trial

We email you if NCT07027969 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Scheduled start: November 1, 2026. Expected completion: March 31, 2030. Last updated on ClinicalTrials.gov: April 17, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.